Loading
Fragments of Epstein-Barr virus DNA in the blood that measure nasopharyngeal carcinoma: used to screen healthy people in endemic regions, to stage, to decide who needs extra treatment after radiotherapy, and to detect relapse.
Quantitative PCR for EBV BamHI-W or EBNA1 sequences in plasma (Lo, 1999) correlates with tumour burden and stage in EBV-associated NPC. Uses: (1) screening: a two-stage plasma EBV DNA test in 20,174 Hong Kong men detected NPC at earlier stage with better survival (Chan, NEJM 2017); (2) prognosis: pretreatment level is independent of TNM and incorporated in proposed staging; (3) response: detectable EBV DNA after chemoradiation identifies high-risk patients who benefit from adjuvant chemotherapy (NRG-HN001 trial design; Chen 2021 capecitabine); (4) surveillance: rising levels precede clinical relapse by months. Standardisation across laboratories (harmonised assays) remains a challenge; NGS-based fragmentomic assays improve specificity. It is the template for ctHPV DNA in oropharyngeal cancer.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag biomarker.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag biomarker.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag biomarker.
Shares Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag biomarker.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag biomarker.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag biomarker.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag biomarker.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag biomarker.